{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T07:42:11Z","timestamp":1772264531877,"version":"3.50.1"},"reference-count":17,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.bbrc.2015.06.122","type":"journal-article","created":{"date-parts":[[2015,6,22]],"date-time":"2015-06-22T17:52:08Z","timestamp":1434995528000},"page":"416-421","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Tumor-suppressive effects of natural-type interferon-\u03b2 through CXCL10 in melanoma"],"prefix":"10.1016","volume":"464","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6437-9337","authenticated-orcid":false,"given":"Hikaru","family":"Kobayashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshimasa","family":"Nobeyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidemi","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2015.06.122_bib1","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1056\/NEJMra052166","article-title":"Melanoma","volume":"355","author":"Miller","year":"2006","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.bbrc.2015.06.122_bib2","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMra041245","article-title":"Management of cutaneous melanoma","volume":"351","author":"Tsao","year":"2004","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.bbrc.2015.06.122_bib3","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib","volume":"366","author":"Sosman","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"Suppl.\u00a06","key":"10.1016\/j.bbrc.2015.06.122_bib4","article-title":"Utility of adjuvant systemic therapy in melanoma","volume":"20","author":"Eggermont","year":"2009","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bbrc.2015.06.122_bib5","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)61033-8","article-title":"Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial","volume":"372","author":"Eggermont","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.bbrc.2015.06.122_bib6","first-page":"73","article-title":"Clinical study of DAV+IFN-\u03b2 therapy (combination adjuvant therapy with intravenous DTIC, ACNU and VCR, and local injection of IFN-\u03b2) for malignant melanoma","volume":"12","author":"Yamamoto","year":"1996","journal-title":"Int. J. Immunother."},{"key":"10.1016\/j.bbrc.2015.06.122_bib7","first-page":"2305","volume":"122","author":"Fujisawa","year":"2012","journal-title":"Jpn. J. Dermatol."},{"key":"10.1016\/j.bbrc.2015.06.122_bib8","doi-asserted-by":"crossref","first-page":"251","DOI":"10.5227\/skincancer.29.251","article-title":"Meranooma feron ijiryouhou tashisetsu-kyoudoukennkyuu no kekkahoukoku (Multicenter study of Feron maintenance therapy for melanoma)","volume":"29","author":"Yamamoto","year":"2014","journal-title":"Skin. Cancer"},{"key":"10.1016\/j.bbrc.2015.06.122_bib9","doi-asserted-by":"crossref","first-page":"47","DOI":"10.5227\/skincancer.1.47","article-title":"Akuseikokusyokusyu niokeru kyokutyuu IFN-\u03b2 no rinnpa ikousei nituite (Lymphatic transferability of local injection of IFN-\u03b2 in malignant melanoma patients)","volume":"1","author":"Yamamoto","year":"1986","journal-title":"Skin. Cancer"},{"key":"10.1016\/j.bbrc.2015.06.122_bib10","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/j.1365-2133.2010.10176.x","article-title":"CXCL10 reduces melanoma proliferation and invasiveness in\u00a0vitro and in\u00a0vivo","volume":"164","author":"Antonicelli","year":"2011","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.bbrc.2015.06.122_bib11","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1097\/CJI.0b013e3181fb045d","article-title":"Interferons induce CXCR3-cognate chemokine production by human metastatic melanoma","volume":"33","author":"Dengel","year":"2010","journal-title":"J.\u00a0Immunother."},{"key":"10.1016\/j.bbrc.2015.06.122_bib12","doi-asserted-by":"crossref","first-page":"4200","DOI":"10.4049\/jimmunol.180.6.4200","article-title":"STAT-1 signaling in human lung fibroblasts is induced by vanadium pentoxide through an IFN-beta autocrine loop","volume":"180","author":"Antao-Menezes","year":"2008","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.bbrc.2015.06.122_bib13","first-page":"287","article-title":"CXCR3, a double-edged sword in tumor progression and angiogenesis","volume":"1836","author":"Billottet","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbrc.2015.06.122_bib14","doi-asserted-by":"crossref","first-page":"e61353","DOI":"10.1371\/journal.pone.0061353","article-title":"Mutant p53 attenuates the anti-tumorigenic activity of fibroblasts-secreted interferon beta","volume":"8","author":"Madar","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bbrc.2015.06.122_bib15","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/sj.onc.1208204","article-title":"Interferons alpha and gamma induce p53-dependent and p53-independent apoptosis, respectively","volume":"24","author":"Porta","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.bbrc.2015.06.122_bib16","doi-asserted-by":"crossref","first-page":"16351","DOI":"10.1074\/jbc.272.26.16351","article-title":"Interferon-gamma modulates a p53-independent apoptotic pathway and apoptosis-related gene expression","volume":"272","author":"Ossina","year":"1997","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.bbrc.2015.06.122_bib17","doi-asserted-by":"crossref","first-page":"583","DOI":"10.3892\/ol.2011.300","article-title":"The emerging role of CXCL10 in cancer (Review)","volume":"2","author":"Liu","year":"2011","journal-title":"Oncol. Lett."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X15301765?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X15301765?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,7,19]],"date-time":"2018-07-19T12:50:30Z","timestamp":1532004630000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X15301765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S0006291X15301765"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2015.06.122","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumor-suppressive effects of natural-type interferon-\u03b2 through CXCL10 in melanoma","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2015.06.122","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}